| scholarly article | Q13442814 |
| P2093 | author name string | Laver WG | |
| Air GM | |||
| Bansal A | |||
| Colacino JM | |||
| Staschke KA | |||
| Baxter AJ | |||
| Hornback WJ | |||
| Munroe JE | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 642-646 | |
| P577 | publication date | 1995-12-01 | |
| P1433 | published in | Virology | Q7934867 |
| P1476 | title | Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en | |
| P478 | volume | 214 |
| Q44497218 | A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding |
| Q39685928 | A reverse genetics approach for recovery of recombinant influenza B viruses entirely from cDNA. |
| Q33842791 | A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity |
| Q40792812 | Apoptosis by influenza viruses correlates with efficiency of viral mRNA synthesis |
| Q33730165 | Approaches and strategies for the treatment of influenza virus infections |
| Q34120005 | Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model |
| Q35882160 | Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. |
| Q28369317 | Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. |
| Q35640944 | Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium |
| Q37112180 | Deletions of neuraminidase and resistance to oseltamivir may be a consequence of restricted receptor specificity in recent H3N2 influenza viruses |
| Q90016287 | Detection and Characterization of Influenza B Virus With Reduced Neuraminidase Susceptibility in a Stem Cell Transplant Recipient |
| Q30308218 | Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay |
| Q27760264 | Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase |
| Q40004651 | Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in Mallard ducks |
| Q56968445 | Evaluation of influenza A virus receptors |
| Q37713074 | Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y. |
| Q28379467 | Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140. |
| Q34695284 | Genetic characterisation of influenza B viruses detected in Singapore, 2004 to 2009. |
| Q50143228 | Identification and characterization of the ficellomycin biosynthesis gene cluster from Streptomyces ficellus |
| Q39563269 | Importance of viral genomic composition in modulating glycoprotein content on the surface of influenza virus particles. |
| Q42755170 | Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics |
| Q30453278 | In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. |
| Q21562135 | Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance |
| Q33787108 | Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice |
| Q90241717 | Influenza Hemagglutinin and Neuraminidase: Yin⁻Yang Proteins Coevolving to Thwart Immunity |
| Q30305461 | Influenza virus neuraminidase inhibitors |
| Q79340361 | Influenza virus resistance to neuraminidase inhibitors |
| Q33922846 | Influenza virus sialidase: a target for drug discovery. |
| Q39027771 | Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility |
| Q24562911 | Influenza: emergence and control |
| Q30425126 | In vitro selection of influenza B viruses with reduced sensitivity to neuraminidase inhibitors |
| Q28263525 | Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors |
| Q33827578 | Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors |
| Q39577999 | Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors |
| Q34077100 | Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility |
| Q27021579 | Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance |
| Q34519220 | Neuraminidase inhibitors for the treatment and prevention of influenza |
| Q30452889 | Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. |
| Q30472797 | New approaches to influenza chemotherapy. Neuraminidase inhibitors |
| Q56785849 | Oseltamivir for treatment and prophylaxis of influenza infection |
| Q34196642 | Oseltamivir: a review of its use in influenza |
| Q30151772 | Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor |
| Q22305941 | Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors |
| Q41312658 | Sialidases: structures, biological significance and therapeutic potential |
| Q30452569 | Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity |
| Q40699560 | The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients |
| Q37975932 | Therapeutics against influenza |
| Q41516241 | Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. |
| Q34229084 | Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza |
| Q33978456 | Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies |
| Q30327955 | Zanamivir: a rational approach to influenza B. |
| Q40419399 | Zanamivir: an influenza virus neuraminidase inhibitor |
| Q34492611 | Zanamivir: an update of its use in influenza |
Search more.